Denecimig (Mim8) Significantly Reduced Annualised Bleeding Rate in People with Hemophilia A, Regardless of Inhibitor Status, in Phase 3 Data Published in NEJM

Denecimig (Mim8) Significantly Reduced Annualised Bleeding Rate in People with Hemophilia A, Regardless of Inhibitor Status, in Phase 3 Data Published in NEJM

Summary

Plainsboro, NJ and Bagsv rd, Denmark, 29 April 29 2026 Today, the New England Journal of Medicine (NEJM) published 26-week results from the phase 3 FRONTIER2 tr

Description

Plainsboro, NJ and Bagsv rd, Denmark, 29 April 29 2026 Today, the New England Journal of Medicine (NEJM) published 26-week results from the phase 3 FRONTIER2 tr

Original reporting

AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.

Open original source

Related coverage